The “Calcium Paradox” due to Ca2+/cAMP Interaction and Antihypertensive Pharmacotherapy: New Avenues for Drug Development
Received Date: Mar 09, 2017 / Accepted Date: Mar 21, 2017 / Published Date: Mar 28, 2017
Abstract
In 2013, we showed that the paradoxical effects (sympathetic hyperactivity) induced by L-type voltage-activated Ca2+ channels (VACC) blockers, named by us “calcium paradox” phenomenon, were potentiated by drugs which increase cytosolic cAMP concentration ([cAMP]c-enhancers), for example rolipram, IBMX and forskolin, indicating that the sympathetic hyperactivity induced by VACC blockers is due to interaction of the Ca2+/cAMP intracellular signaling pathways (Ca2+/cAMP interaction). Then, the pharmacological handling of this interaction produced by combined use of the L-type VACC blockers prescribed in the antihypertensive therapy, and [cAMP]c-accumulating compounds prescribed in the antidepressive therapy, could represent a potential cardiovascular deleterious effect for hypertensive patients due to stimulation of sympathetic hyperactivity. Then, we discussed the role of Ca2+/cAMP interaction for antihypertensive pharmacotherapy. In conclusion, this interaction could be a novel therapeutic target for drug development.
Keywords: Ca2+/cAMP interaction; Sympathetic neurotransmission; Hypertension
Citation: Bueno LB, Neto CA (2017) The “Calcium Paradox” due to Ca2+/cAMP Interaction and Antihypertensive Pharmacotherapy: New Avenues for Drug Development. Cardiovasc Ther 2: 117.
Copyright: © 2017 Bueno LB, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Share This Article
黑料网 Journals
Article Usage
- Total views: 3590
- [From(publication date): 0-2017 - Nov 25, 2024]
- Breakdown by view type
- HTML page views: 2895
- PDF downloads: 695
